Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up. World J Gastroenterol 2011; 17(16): 2143-2149 [PMID: 21547136 DOI: 10.3748/wjg.v17.i16.2143]
Corresponding Author of This Article
Yong-Song Guan, Professor, Department of Oncology West China Hospital, Sichuan University, 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China. yongsongguan@yahoo.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Changes in leukocytes before and after treatment
Group
Change degree (×109/L)
n (%)
< 4.0
< 3.0
< 2.0
Gene group
12 (25.0)
4 (8.3)
2 (4.2)
18 (37.5)
Control group
8 (13.3)
20 (33.3)
11 (18.3)
39 (65.0)
Table 4 Changes in Karnofsky index before and after treatment
Group
Upgrade > 20 points
Upgrade > 10 points
No changes
Downgrade > 10 points
Total upgrade[n (%)]
Gene group
14
28
18
8
42 (61.8)
Control group
12
24
18
28
36 (43.9)
Table 5 Therapeutic effect evaluated following response evaluation criteria for solid tumors 2 mo after treatment
Group
n
CR
PR
NC
PD
Effective rate (CR + PR)
Gene group
68
0
46
15
7
67.60%
Control group
82
0
42
27
13
51.20%
Citation: Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up. World J Gastroenterol 2011; 17(16): 2143-2149